Children with endemic Burkitt lymphoma are deficient in EBNAl-specific IFN-γ T cell responses

International Journal of Cancer

Volumn 124, Issue 7, 2009, Pages 1721-1726

  Moormann, Ann M ^a   Heller, Kevin N ^b   Chelimo, Kiprotich ^c   Embury, Paula ^a   Ploutz Snyder, Robert ^d   Otieno, Juliana A ^e   Oduor, Margaret ^e   Münz, Christian ^b   Rochford, Rosemary ^d  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^d State University of New York Upstate Medical University: College of Medicine   (United States)

^e New Nyanza Provincial General Hospital   (Kenya)

Author keywords

Burkitt lymphoma; EBNA1; IFN ; Malaria

Indexed keywords

ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 1; GAMMA INTERFERON; HYDROLASE; IMMUNOGLOBULIN G1; PROTOZOAL PROTEIN; UNCLASSIFIED DRUG; EBV ENCODED NUCLEAR ANTIGEN 1; EBV-ENCODED NUCLEAR ANTIGEN 1; IMMUNOGLOBULIN G;

AFRICA; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; BURKITT LYMPHOMA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; ENDEMIC DISEASE; ENVIRONMENTAL EXPOSURE; ENZYME LINKED IMMUNOSPOT ASSAY; EPIDEMIOLOGICAL DATA; EPSTEIN BARR VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; KENYA; MALARIA; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; T LYMPHOCYTE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; VIROLOGY; VIRUS INFECTION; VIRUS LOAD;

BURKITT LYMPHOMA; CHILD; ENDEMIC DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN G; INTERFERON-GAMMA; KENYA; T-LYMPHOCYTES; VIRAL LOAD;

EID: 61449260054     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24014     Document Type: Article

References (20)

1. Crawford DH. Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci 2001;356:461-73.
2. Mwanda OW, Rochford R, Moormann AM, MacNeil A, Whalen C, Wilson ML. Burkitt's lymphoma in Kenya: geographical, age, gender and ethnic distribution. East Afr Med J 2004:S68-S77.
3. Moormann AM, Chelimo K, Sumba PO, Tisch DJ, Rochford R, Kazura JW. Exposure to holoendemic malaria results in suppression of Epstein-Barr virus-specific T cell immunosurveillance in Kenyan children. J Infect Dis 2007;195:799-808.
4. Blake N, Lee S, Redchenko I, Thomas W, Steven N, Leese A, Steiger- wald-Mullen P, Kurilla MG, Frappier L, Rickinson A. Human CD81 T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 1997;7:791-802.
5. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G, Kurilla MG, Masucci MG. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995;375:685-8.
6. Yin Y, Manoury B, Fahraeus R. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 2003;301:1371-k
7. Nikiforow S, Bottomly K, Miller G, Munz C. Cytolytic CD4(1)-T- cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B- cell proliferation. J Virol 2003;77:12088-104.
8. Heller KN, Upshaw J, Seyoum B, Zebroski H, Munz C. Distinct memory CD41 T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers. Blood 2007; 109:1138-46.
9. Paludan C, Bickham K, Nikiforow S, Tsang ML, Goodman K, Hane- kom WA, Fonteneau JF, Stevanovic S, Munz C. Epstein-Barr nuclear antigen 1-specific CD4(1) Th1 cells kill Burkitt's lymphoma cells. J Immunol 2002;169:1593-603.
10. Rainey JJ, Omenah D, Sumba PO, Moormann AM, Rochford R, Wilson ML. Spatial clustering of endemic Burkitt's lymphoma in high- risk regions of Kenya. Int J Cancer 2007;120:121-7.
11. Singh S, Kennedy MC, Long CA, Saul AJ, Miller LH, Stowers AW. Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-ter- minal merozoite surface protein 1. Infect Immun 2003;71:6766-74.
12. Moormann AM, Chelimo K, Sumba OP, Lutzke ML, Ploutz-Snyder R, Newton D, Kazura J, Rochford R. Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J Infect Dis 2005;191:1233-8.
13. Piriou E, van Dort K, Nanlohy NM, van Oers MH, Miedema F, van Baarle D. Loss of EBNA1-specific memory CD41 and CD81 T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma. Blood 2005;106:3166-74.
14. de-The G. Epstein-Barr virus and Burkitt's lymphoma worldwide: the causal relationship revisited. IARC Sci Publ 1985:165-76.
15. Voo KS, Fu T, Wang HY, Tellam J, Heslop HE, Brenner MK, Rooney CM, Wang RF. Evidence for the presentation of major histocompati- bility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD81 T lymphocytes. J Exp Med 2004;199:459-70.
16. Urban BC, Ferguson DJ, Pain A, Willcox N, Plebanski M, Austyn JM, Roberts DJ. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature 1999;400:73-7.
17. Cao K, Moormann AM, Lyke KE, Masaberg C, Sumba OP, Doumbo OK, Koech D, Lancaster A, Nelson M, Meyer D, Single R, Hartzman RJ, et al. Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci. Tissue Antigens 2004;63:293-325.
18. Wilson NS, Behrens GM, Lundie RJ, Smith CM, Waithman J, Young L, Forehan SP, Mount A, Steptoe RJ, Shortman KD, de Koning-Ward TF, Belz GT, et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol 2006;7:165-72.
19. Huaman MC, Martin LB, Malkin E, Narum DL, Miller LH, Mahanty S, Long CA. Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum merozoite surface pro- tein-1 in vaccinated volunteers. J Immunol 2008;180:1451-61.
20. Heller KN, Arrey F, Steinherz P, Portlock C, Chadburn A, Kelly K, unz C. Patients with Epstein Barr virus-positive lymphomas have decreased CD4(+) T-cell responses to the viral nuclear antigen 1. Int J Cancer 2008;123:2824-31.